Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia

Shots: Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…

BySaurabh ChaubeyJanuary 8, 2024

VIEWPOINTS

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

Shots:Brian talked about the $17 million in Series A funding led by Blue Ledge Capital including other venturesBrian also spoke about multiple products being developed in Qnovia’s pipeline. The funding will advance its NRT drug candidate through an IND submission in 2023The interview gives an understanding of how Qnovia is developing innovative…

BySenior EditorDecember 27, 2022

VIEWPOINTS

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Shots:Brian spoke about why Respira Technologies has been rebranded as QnoviaBrian also talked about how Qnovia is working to advance its first inhalable prescription smoking cessation therapy and its applicationsThe interview summarizes how this rebranding will accelerate Qnovia’s technology and products from others in the biotechnology space Smriti: Would you please start off…

BySenior EditorDecember 12, 2022

Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia

Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Contact US

OUR INFORMATION

FOLLOW US